How to Choose a Rehab: A Practical, Evidence-Based Guide

Most people choose a treatment program in the worst possible conditions: frightened, exhausted, often within a day or two of a crisis, and while being marketed to by an industry that knows exactly how that feels. This guide is built to be useful in that state.

One thing worth saying before anything else. There is real urgency about starting care - NIDA’s principles note that “potential patients can be lost if treatment is not immediately available or readily accessible” (NIDA). There is no urgency about signing a contract this afternoon. Anyone applying that second kind of pressure is telling you something about themselves.

If you or someone you love is in crisis, call or text 988 anytime. For free, confidential treatment referrals, call SAMHSA’s National Helpline at 1-800-662-HELP (4357), 24/7.

The three filters that matter most

If you have ten minutes rather than ten hours, ask only these:

1. Is the program licensed by the state, and accredited?
2. If opioids or alcohol are involved, does it offer or arrange medication?
3. Does the level of care match the person, rather than what the program happens to sell?

The second one is where we would start, so it comes first.

Medication access is the clearest quality signal

For opioid use disorder, this is not a preference. The National Academies of Sciences, Engineering, and Medicine put it in language that leaves no room: “Withholding or failing to have available all U.S. Food and Drug Administration-approved classes of medication for the treatment of opioid use disorder in any care or criminal justice setting is denying appropriate medical treatment” (National Academies).

The same report addresses the argument you will hear from programs that do not offer them: “Withholding them on ideological or other non-evidence-based grounds is denying people needed medical care.” Methadone, buprenorphine and extended-release naltrexone are described there as “safe and highly effective medications.”

The outcome that matters most is survival. NIDA states that “people with opioid use disorder who are treated with methadone or buprenorphine are less likely to die or to have an overdose than those who do not receive treatment” (NIDA). And yet, on the same page: “fewer than 1 in 5 people with opioid use disorder are treated with these medications.”

So when you call a program and ask whether they allow buprenorphine or methadone, you are not asking a preference question. You are asking whether their care matches the national evidence base. If the answer is no, or hedged, or wrapped in language about “true sobriety,” that is your filter working.

Alcohol use disorder has medications too - acamprosate, disulfiram and naltrexone - and NIDA’s principles note that medications “are an important element of treatment for many patients, especially when combined with counseling and other behavioral therapies” (NIDA). Our guide on medication-assisted treatment explains how each works.

If someone you love is already in a program that refuses medication, the move is not to pull them out today. It is to talk to a clinician, or call the helpline above, and get advice for that specific situation.

Licensing and accreditation: a floor, not a promise

State licensure is the baseline. Accreditation by a body such as CARF or the Joint Commission sits on top of it. CARF describes accreditation as “a review to determine if the programs and services offered by providers meet defined international standards of quality in health and human services” (CARF).

Read that carefully, because it describes a review against standards - not a measure of whether people get better.

Two things worth knowing. For opioid treatment programs - the federally regulated category of clinic that dispenses methadone, not every program that treats opioid use disorder - accreditation is not optional at all: federal rules require SAMHSA certification, accreditation by a SAMHSA-designated body, and compliance with state law (42 CFR 8.11). And oversight of accreditation itself has documented gaps - an HHS Inspector General review concluded that SAMHSA’s oversight generally ensured accreditation requirements were verified, while also finding that its procedures “did not require verification that accreditation bodies’ … records contained sufficient detail supporting each accreditation decision” (HHS OIG).

Treat accreditation as a floor to insist on, not a verdict to relax about.

”Rehab” is not one thing

Programs differ by intensity, and the right intensity depends on the person - their withdrawal risk, medical and mental health needs, and what their home life will support.

The American Society of Addiction Medicine organizes programs into levels of care so that referrals can be matched to the individual, as the Surgeon General’s report describes (Facing Addiction in America). That report also sketches what a full course can look like for a severe disorder: a short medically managed withdrawal period, then one to three months of intensive rehabilitative care, then continuing care stepping down from intensive outpatient to routine outpatient.

The principle underneath is the part to hold on to. NIDA states it plainly (NIDA): “No single treatment is appropriate for everyone,” and “matching treatment settings, interventions, and services to an individual’s particular problems and needs is critical.” A program that recommends the same thing to everyone who calls is not assessing anyone.

Our guide on levels of care walks through what each setting involves, and what medical detox is covers the withdrawal stage specifically.

One correction worth making early: detox is not treatment. NIDA’s principles are direct that medically assisted withdrawal “is only the first stage of addiction treatment and by itself does little to change long-term drug [use]” (NIDA). A program selling a detox stay as a complete solution is selling the first week of something.

How long, and why that question matters

Length of stay is not a marketing feature - it is one of the better-studied variables in the field. NIDA’s principles (NIDA) state that “remaining in treatment for an adequate period of time is critical,” that most people need “at least 3 months in treatment to significantly reduce or stop their drug use,” and that “the best outcomes occur with longer durations of treatment.”

They also say something that reframes what a good program does: “because individuals often leave treatment prematurely, programs should include strategies to engage and keep patients in treatment.” Retention is the program’s job, not just the patient’s willpower.

For serious disorders, the Surgeon General’s report describes staying engaged in the treatment process for at least a year - across several services, not in one building. That is a very different picture from the 28-day stay the industry has trained everyone to imagine.

Co-occurring conditions

Depression, anxiety, PTSD and substance use disorders travel together often enough that any program worth choosing screens for both. NIDA’s position is that “the high rate of co-occurring substance use and other mental disorders shows the need for an integrated approach to identify and treat these disorders at the same time,” and that “integrated treatment leads to better health outcomes” (NIDA).

Ask specifically: who diagnoses mental health conditions here, and who treats them? “We refer out” is an answer - just make sure you know what it means for continuity. Our guide on dual diagnosis treatment covers this in more depth.

Questions to ask before you commit

The National Institute on Alcohol Abuse and Alcoholism publishes ten recommended questions in its Alcohol Treatment Navigator. They are written for alcohol treatment - two of them are alcohol-worded - but the rest apply to any program, and the medication question adapts directly:

1. Availability - if we choose you, how soon could treatment begin?
2. Costs and insurance - can you help me estimate the cost? Will insurance cover it?
3. Credentials - are you licensed and accredited? What are your counseling staff’s qualifications? Is the doctor board certified in addiction medicine or addiction psychiatry?
4. Assessment - how do you establish a treatment plan? Do you start with a complete assessment and diagnosis?
5. Treatment approach - what is your approach, and which therapies do you use?
6. Medication - can you prescribe or arrange medication if it is appropriate? (NIAAA’s version asks about alcohol medications; ask the same question about methadone, buprenorphine and naltrexone if opioids are involved.)
7. Other conditions - how do you help people address other mental health or medical issues?
8. Expectations - what do you expect of patients and their families during treatment?
9. Relapse - what do you do if someone returns to use while in treatment?
10. Afterwards - is ongoing recovery support available?

NIAAA is honest about what its five signs of quality care buy you: “There are no guarantees, but providers with all five signs are more likely to offer treatment based on the latest scientific research. This can increase your odds of success” (NIAAA).

Red flags, and how to raise them

None of the following proves anything about a specific program. They are things to ask about, and the answer tells you more than the question does.

• Anyone being paid to send you somewhere. Ask directly whether the person advising you receives anything for the referral. Government reviewers have documented referral-for-payment arrangements in this sector, including per-patient payments to housing operators and unnecessary drug testing billed to insurance (GAO). Federal law at 18 U.S.C. 220 makes it an offence to knowingly and willfully solicit, receive, pay or offer remuneration for referrals to recovery homes, clinical treatment facilities and laboratories, with respect to services covered by a health care benefit program. It carries statutory exceptions, including bona fide employment arrangements where pay does not vary with referral volume - so a salaried admissions worker is not what the statute is aimed at. The point of asking is to find out how someone is compensated, not to catch anyone out.
• A call centre that will not name the facility. Marketing companies and referral services are not the same as programs. Ask who you are speaking to and what they are paid for.
• Guarantees. NIAAA’s own framing is that there are no guarantees, even for providers showing every sign of quality care.
• Pressure to decide today, or an offer to fly someone somewhere immediately. Urgency about starting care is reasonable; urgency about signing today is a sales technique.
• Refusal to allow medication for opioid use disorder, per the section above.
• One programme for everyone, which contradicts the matching principle.
• Vagueness about total cost. Ask for it in writing, and ask what insurance actually covers. Our guide on how to pay for rehab covers the options.

Where to search

Start with FindTreatment.gov, SAMHSA’s official locator, or call the National Helpline at 1-800-662-HELP (4357). For alcohol specifically, NIAAA’s Alcohol Treatment Navigator is a free NIH tool built for exactly this decision. Your state substance use agency can confirm whether a program is licensed.

Search these before searching a general web engine, where the first page is bought.

FAQ

Is expensive treatment better treatment? None of the federal sources cited here treats price as a marker of quality. What the sources support is assessment, medication access, individualized planning, integrated mental health care and continuing support - none of which requires a luxury setting.

Is inpatient always better than outpatient? No. The right level depends on the person’s withdrawal risk, medical and psychiatric needs, and home environment. NIDA is explicit that no single treatment is appropriate for everyone.

Is medication just swapping one addiction for another? No. The National Academies describe methadone, buprenorphine and extended-release naltrexone as “safe and highly effective,” and withholding them on ideological grounds as denying needed medical care.

What if a program will not give me a clear price? Ask again in writing, and treat continued vagueness as information. NIAAA lists cost and insurance among the ten questions every program should be able to answer.

Sources

• National Academies of Sciences, Engineering, and Medicine - Medications for Opioid Use Disorder Save Lives
• National Institute on Drug Abuse - Medications for Opioid Use Disorder, Co-Occurring Substance Use and Other Mental Disorders, and Principles of Drug Addiction Treatment (3rd ed.)
• U.S. Surgeon General - Facing Addiction in America, Chapter 4
• National Institute on Alcohol Abuse and Alcoholism - Alcohol Treatment Navigator: the 10 recommended questions and the five signs of quality care
• U.S. Government Publishing Office - 42 CFR 8.11, Opioid treatment program certification and 18 U.S.C. 220, Illegal remunerations for referrals
• U.S. Government Accountability Office - Substance Use Disorder: Information on Recovery Housing Prevalence, Selected States’ Oversight, and Funding (GAO-18-315)
• HHS Office of Inspector General - SAMHSA’s oversight of CARF accreditation of opioid treatment programs
• CARF International - Accreditation
• SAMHSA - National Helpline and FindTreatment.gov

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. It does not endorse any facility or program.